Robbins Farley’s Royalty Pharma RPRX Stock Holding History

Robbins Farley’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-20	Closed	-$528	–	167
2024 Q2	$528	Hold	20	–	–	﹤0.01%	147
2024 Q1	$608	Hold	20	–	–	﹤0.01%	144
2023 Q4	$562	Buy	+20	New	+$550	﹤0.01%	148

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Robbins Farley's RPRX Position: Q3 2024 in Review

Robbins Farley sold out of Royalty Pharma (RPRX) in Q3 2024, closing a stake of 20 shares — an estimated $528 sold.

Robbins Farley first reported a position in RPRX in Q4 2023 and held it in 3 quarters. The position peaked at $608 in Q1 2024. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

Robbins Farley reported no remaining Royalty Pharma position as of Q3 2024 after selling out during the quarter.
Robbins Farley sold 20 Royalty Pharma shares in Q3 2024, an estimated $528.
Robbins Farley first reported a position in Royalty Pharma in Q4 2023 and held it in 3 quarters.
Robbins Farley's Royalty Pharma position peaked at $608 in Q1 2024.
395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on Robbins Farley's 13F filing for Q3 2024, filed 16 Oct 2024.